The role of membrane transporters in ovarian cancer chemoresistance and prognosis

被引:14
作者
Cerovska, Ela [1 ]
Elsnerova, Katerina [1 ,2 ,3 ]
Vaclavikova, Radka [1 ,3 ]
Soucek, Pavel [1 ,3 ]
机构
[1] Natl Inst Publ Hlth, Toxicogen Unit, Prague, Czech Republic
[2] Charles Univ Prague, Fac Med 3, Prague, Czech Republic
[3] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic
关键词
Ovarian cancer; chemoresistance; membrane transporters; expression; prognosis; SINGLE NUCLEOTIDE POLYMORPHISMS; ORGANIC CATION TRANSPORTERS; MULTIDRUG-RESISTANCE; ABC TRANSPORTER; P-GLYCOPROTEIN; CISPLATIN RESISTANCE; DRUG-RESISTANCE; GENE-EXPRESSION; CELLULAR ACCUMULATION; PACLITAXEL RESISTANCE;
D O I
10.1080/17425255.2017.1332179
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Ovarian cancer has the highest mortality rate of all cancers in women. There is currently no effective method for early diagnosis, limiting the precision of clinical expectations. Predictions of therapeutic efficacy are currently not available either. Specifically, the development of chemoresistance against conventional chemotherapy poses a fundamental complication. Some membrane transporters have been reported to influence chemoresistance, which is often associated with a poor prognosis. Areas covered: The aim of this article is to review the existing information about membrane transporters and their role in both ovarian cancer chemoresistance and its outcomes. We then highlight limitations of current methodologies and suggest alternatives providing avenues for future research. Expert opinion: Membrane transporters play an important role in development of chemoresistance and affect prognosis of ovarian cancer patients; however, due to variations in methodology and in patient populations, their specific roles have yet to be clarified. For further evaluation of the clinical utility of membrane transporters, it is essential to validate results and improve methods for marker assessment across laboratories. A promising area for future research is to identify the genetic variability in potential markers in peripheral blood. These markers would then stratify patients into defined groups for optimal intervention.
引用
收藏
页码:741 / 753
页数:13
相关论文
共 131 条
[31]   LDL-cholesterol signaling induces breast cancer proliferation and invasion [J].
dos Santos, Catarina Rodrigues ;
Domingues, Germana ;
Matias, Ines ;
Matos, Joao ;
Fonseca, Isabel ;
de Almeida, Jose Mendes ;
Dias, Sergio .
LIPIDS IN HEALTH AND DISEASE, 2014, 13
[32]  
Duan ZF, 2004, MOL CANCER THER, V3, P833
[33]   Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene [J].
Ee, PLR ;
Kamalakaran, S ;
Tonetti, D ;
He, XL ;
Ross, DD ;
Beck, WT .
CANCER RESEARCH, 2004, 64 (04) :1247-1251
[34]   The association of taxane resistance genes with the clinical course of ovarian carcinoma [J].
Ehrlichova, Marie ;
Mohelnikova-Duchonova, Beatrice ;
Hrdy, Jiri ;
Brynychova, Veronika ;
Mrhalova, Marcela ;
Kodet, Roman ;
Rob, Lukas ;
Pluta, Marek ;
Gut, Ivan ;
Soucek, Pavel ;
Vaclavikova, Radka .
GENOMICS, 2013, 102 (02) :96-101
[35]   Targeting the ABCB4 gene to control cholesterol homeostasis [J].
Elferink, Ronald P. J. Oude ;
Beuers, Ulrich .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (10) :1173-1182
[36]   Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma [J].
Elsnerova, Katerina ;
Mohelnikova-Duchonova, Beatrice ;
Cerovska, Ela ;
Ehrlichova, Marie ;
Gut, Ivan ;
Rob, Lukas ;
Skapa, Petr ;
Hruda, Martin ;
Bartakova, Alena ;
Bouda, Jiri ;
Vodicka, Pavel ;
Soucek, Pavel ;
Vaclavikova, Radka .
ONCOLOGY REPORTS, 2016, 35 (04) :2159-2170
[37]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386
[38]   RISKS OF CANCER IN BRCA1-MUTATION CARRIERS [J].
FORD, D ;
EASTON, DF ;
BISHOP, DT ;
NAROD, SA ;
GOLDGAR, DE ;
HAITES, N ;
MILNER, B ;
ALLAN, L ;
PONDER, BAJ ;
PETO, J ;
SMITH, S ;
STRATTON, M ;
LENOIR, GM ;
FEUNTEUN, J ;
LYNCH, H ;
ARASON, A ;
BARKARDOTTIR, R ;
EGILSSON, V ;
BLACK, DM ;
KELSELL, D ;
SPURR, N ;
DEVILEE, P ;
CORNELISSE, CJ ;
VARSEN, H ;
BIRCH, JM ;
SKOLNICK, M ;
SANTIBANEZKOREF, MS ;
TEARE, D ;
STEEL, M ;
PORTER, D ;
COHEN, BB ;
CAROTHERS, A ;
SMYTH, E ;
WEBER, B ;
NEWBOLD, B ;
BOEHNKE, M ;
COLLINS, FS ;
CANNONALBRIGHT, LA ;
GOLDGAR, D .
LANCET, 1994, 343 (8899) :692-695
[39]   Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors [J].
Gazzaniga, Paola ;
Naso, Giuseppe ;
Gradilone, Angela ;
Cortesi, Enrico ;
Gandini, Orietta ;
Gianni, Walter ;
Fabbri, Maria Agnese ;
Vincenzi, Bruno ;
di Silverio, Franco ;
Frati, Luigi ;
Agliano, Anna Maria ;
Cristofanilli, Massimo .
INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (10) :2437-2447
[40]   Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions [J].
Gillett, Jean-Pierre ;
Wang, Junbai ;
Calcagno, Anna Maria ;
Green, Lisa J. ;
Varma, Sudhir ;
Elstrand, Mari Bunkholt ;
Trope, Claes G. ;
Ambudkar, Suresh V. ;
Davidson, Ben ;
Gottesman, Michael M. .
MOLECULAR PHARMACEUTICS, 2011, 8 (06) :2080-2088